Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) will report its fourth quarter 2020 financial results and operational highlights on March 1, 2021, post U.S. market closure. The company develops next-generation vaccines, including NVX-CoV2373 against COVID-19 and NanoFlu™, which recently met its Phase 3 trial objectives for influenza. Both vaccine candidates utilize the Matrix-M™ adjuvant to boost immune response. A conference call is scheduled for 4:30 p.m. ET on the same date, with a replay available post-event.

Positive

• NVX-CoV2373 and NanoFlu™ are in late-stage clinical trials with potential for regulatory submission.
• NanoFlu™ met all primary objectives in its pivotal Phase 3 clinical trial.

Negative

• None.

GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2020 financial results and operational highlights following the close of U.S. financial markets on Monday, March 1, 2021.

Conference call details are as follows:
Date: Time: Dial-in number: Passcode: Webcast:	March 1, 2021 4:30 p.m. U.S. Eastern Time (ET) (877) 212-6076 (Domestic) or (707) 287-9331 (International) 3797013 www.novavax.com/events
Conference call and webcast replay:
Date: Dial-in number: Passcode: Webcast:	Starting at 7:30 p.m. ET, March 1, 2021 (855) 859-2056 (Domestic) or (404) 537-3406 (International) 3797013 www.novavax.com/events, until June 1, 2021

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:         
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com

Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
media@novavax.com

FAQ

What are Novavax's financial results for Q4 2020?

Novavax will announce its fourth quarter 2020 financial results on March 1, 2021.

When will Novavax hold its conference call for Q4 2020?

The conference call will take place on March 1, 2021, at 4:30 p.m. ET.

What is NVX-CoV2373?

NVX-CoV2373 is Novavax's vaccine candidate against SARS-CoV-2, currently in late-stage clinical trials.

What was the outcome of the NanoFlu™ clinical trial?

NanoFlu™ met all primary objectives in its pivotal Phase 3 clinical trial.